Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL34378 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30361066 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29599595 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29363851 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL53998 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30465862 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29588704 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29566149 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL1560198 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2315085 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105698-B2 | Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2- methoxybenzenesulfonamide | RAGACTIVES, S.L. (ES) | 2006-09-12 | — | — | US | claimed |
| US-H2154-H1 | Process for preparing R- and S-isomers of (R)-5-(2-( (2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | FARMAK, A.S. (CZ) | 2006-04-04 | — | — | US | claimed |
| US-20050079589-A1 | Process for preparing R- and S-isomers of (R)-5-(2-( (2-(2-ethoxyphenoxy) ethyl) amino) propyl) -2-methoxybenzenesulfonamide | FARMAK, A.S. (CZ) | 2005-04-14 | — | — | US | claimed |
| EP-1522538-A2 | METHOD OF SEPARATING R(-)- AND S(+)-5- 2- 2-(2-ETHOXYPHENOXY)ETHYL]AMINO]PROPYL-2-METHOXYBENZENE-SULPHONAMIDE | Ragactives, S.L. (ES) | 2005-04-13 | — | — | EP | claimed |
| US-20050004398-A1 | Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide | RAGACTIVES, S.L. | 2005-01-06 | — | — | US | claimed |
| EP-0710486-A1 | REMEDY FOR URINATION DISORDER ACCOMPANYING PROSTATIC HYPERTROPHY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-05-08 | — | — | EP | claimed |
| US-4761500-A | CONGESTIVE HEART FAILURE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-08-02 | — | — | US | claimed |
| EP-2172443-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | HAMARI CHEMICALS LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8222452-B2 | Method for producing optically active amines | HAMARI CHEMICALS, LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | HAMARI CHEMICALS, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2172443-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | Hamari Chemicals, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2004006829-A3 | METHOD OF SEPARATING R(-)- AND S(+)-5-[2-[[2-(2-ETHOXYPHENOXY)ETHYL]AMINO]PROPYL-2-METHOXYBENZENE-SULPHONAMIDE | RAGACTIVES SL (ES) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004006829-A2 | METHOD OF SEPARATING R(-)- AND S(+)-5-[2-[[2-(2-ETHOXYPHENOXY)ETHYL]AMINO]PROPYL-2-METHOXYBENZENE-SULPHONAMIDE | RAGACTIVES, S.L. (ES) | 2004-01-22 | — | — | WO | disclosed |
| EP-0710486-A1 | REMEDY FOR URINATION DISORDER ACCOMPANYING PROSTATIC HYPERTROPHY | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5447958-A | Treatment of hypertension, congestive heart failure, angina pectoris, lower urinary tract dysfunction, prostatic hypertrophy | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-09-05 | — | — | US | disclosed |
| US-5391825-A | ADRENERGIC BLOCKING AGENTS; CARDIOVASCULAR DISORDERS; UREGENITAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-02-21 | — | — | US | disclosed |
| US-4761500-A | CONGESTIVE HEART FAILURE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-08-02 | — | — | US | disclosed |
| US-4731478-A | ADRENERGIC BLOCKING AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | ADRA1A 1742/4885ADRA1D 3128/4885ADRA1B 2618/4885 |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | INMT, HNMT, PADI3 | ADRA1A 1737/4885ADRA1D 1633/4885ADRA1B 1712/4885 |
| US-20050004398-A1 | Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide | ADRB2, ADRB1, ADRA2B | ADRA1A 14/4885ADRA1D 17/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.